Future research may also attempt to optimize the PMCA assay to screen biological products for other misfolded protein aggregates implicated in more prevalent neurodegenerative diseases, such as amyloid-beta (Aβ) and tau in Alzheimer’s disease and alpha-synuclein (α-syn) in Parkinson’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.